Is Cryo-Cell International, Inc. overvalued or undervalued?

As of 18 October 2022, the valuation grade for Cryo-Cell International, Inc. moved from fair to risky, indicating a significant downgrade in its financial outlook. The company appears to be overvalued based on its current metrics, particularly given its negative P/E ratio and price-to-book value of -5.02. Additionally, the EV to EBITDA ratio stands at 15.97, which is notably high compared to its peers.
In comparison to similar companies, Cryo-Cell's valuation is starkly unfavorable; for instance, Bristow Group, Inc. has a P/E of 9.07 and an EV to EBITDA of 7.42, showcasing a more attractive investment profile. Other peers, such as Seacor Marine Holdings, Inc. and ModivCare, Inc., also reflect risky valuations but with less severe metrics than Cryo-Cell. Given these factors, the company is assessed as overvalued, particularly in light of its poor stock performance relative to the S&P 500, where it has underperformed significantly over the past year and beyond.